{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267200","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.205316+00:00","generated_at":"2026-06-09T04:08:29.935621+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025","bullets":["Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.","Cash $11M at Sep 30, 2023; plus $10.2M expected from CPRIT grant through 2024, providing runway into 2025.","Completed dosing in Cohort 4 of Phase 1 ReSPECT-LM trial; new survival data from Phase 2 ReSPECT-GBM to be presented at SNO Nov 2023.","Appointed Pius Maliakal, Ph.D. as VP of Clinical Operations; transferred CNSide biomarker assay from Biocept.","Grant revenue $1.2M in Q3 from CPRIT; total grant awards $3M from NIH and $17.6M from CPRIT."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267200","json":"https://secwatch.observer/filing/0001193125-23-267200.json","markdown":"https://secwatch.observer/filing/0001193125-23-267200.md","text":"https://secwatch.observer/filing/0001193125-23-267200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/0001193125-23-267200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/d578460d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:08:29.935621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76e280d09b0ad54d713ede5480125a0dbc03e596","claim":"PLUS THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: net income $(3.2) million, or $(1.00) per share, EPS $(1.00) per share.","evidence_excerpt":"Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000119312523267200/0001193125-23-267200-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"$(3.2) million, or $(1.00) per share"},{"label":"EPS","value":"$(1.00) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}